{"groups":[{"description":"Patients undergo collection of bone marrow aspirate and blood for high-throughput drug sensitivity assay and mutational analysis using next generation sequencing. Patients and their treating physicians receive the results of the tests. Treatment decisions are then made by the patients and their treating physicians.\n\nBiospecimen Collection: Undergo collection of bone marrow aspirate and blood\n\nHigh Throughput Screening: Anti-tumor drugs are tested against myeloma cells in the laboratory, in a high-throughput drug sensitivity assay\n\nLaboratory Biomarker Analysis: Correlative studies","id":"FG000","title":"Device Feasibility (High-throughput Assay, Sequencing)"}],"periods":[{"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"40"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"40"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"0"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"preAssignmentDetails":"Of 55 screened participants, 40 met inclusion criteria and were enrolled."}